Tozinameran
drug drugOn this page
Also known as BNT-162B2Bnt162b2ComirnatyComirnaty mrnaPfizer covid-19 vaccineRna ingredient bnt-162b2
Summary
Tozinameran (CHEMBL4650429) is an approved vaccine component; indicated across 6 conditions including severe acute respiratory syndrome and allergic disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Vaccine component
- Indications: 6 conditions
- Clinical trials: 80
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650429 |
| Name | Tozinameran |
| Type | Vaccine component |
| Max phase | 4 |
Also known as: BNT-162B2, Bnt162b2, BNT162B2, Comirnaty, Comirnaty mrna, Pfizer covid-19 vaccine, Rna ingredient bnt-162b2, Tozinameran, TOZINAMERAN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 4 | MONDO:0005091 | MONDO:0100096 |
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| allergic disease | 2 | MONDO:0005271 | MONDO:0005271 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 80.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 20 |
| Not specified | 20 |
| PHASE3 | 18 |
| PHASE4 | 12 |
| PHASE1/PHASE2 | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04588480 | PHASE4 | COMPLETED | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults |
| NCT04775069 | PHASE4 | COMPLETED | Antibody Response to COVID-19 Vaccines in Liver Disease Patients |
| NCT04780659 | PHASE4 | COMPLETED | COVID-19 Vaccination of Immunodeficient Persons (COVAXID) |
| NCT05057169 | PHASE4 | COMPLETED | Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study) |
| NCT05057182 | PHASE4 | COMPLETED | Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study) |
| NCT05075538 | PHASE4 | TERMINATED | COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 |
| NCT05168709 | PHASE4 | COMPLETED | Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction |
| NCT05231005 | PHASE4 | UNKNOWN | Fourth BNT162b2 COVID-19 Vaccine Dose |
| NCT05329064 | PHASE4 | UNKNOWN | Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children |
| NCT05343871 | PHASE4 | COMPLETED | Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial |
| NCT05406908 | PHASE4 | COMPLETED | Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases |
| NCT06189040 | PHASE4 | COMPLETED | Immunogenicity After COVID-19 Vaccines in Adapted Schedules |
| NCT07069309 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years |
| NCT07222384 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 |
| NCT07300839 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age |
| NCT04368728 | PHASE2/PHASE3 | COMPLETED | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals |
| NCT04713553 | PHASE3 | COMPLETED | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants |
| NCT04754594 | PHASE2/PHASE3 | COMPLETED | To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older |
| NCT04816643 | PHASE3 | COMPLETED | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children |
| NCT04816669 | PHASE3 | COMPLETED | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults |
| NCT04887948 | PHASE3 | COMPLETED | Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 |
| NCT04955626 | PHASE3 | COMPLETED | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. |
| NCT05047640 | PHASE3 | TERMINATED | COVID-19 3rd Dose Vaccine in Transplant Patients |
| NCT05124171 | PHASE3 | UNKNOWN | Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination |
| NCT05188677 | PHASE3 | COMPLETED | Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults |
| NCT05225285 | PHASE3 | UNKNOWN | Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents |
| NCT05293665 | PHASE3 | UNKNOWN | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| NCT05310084 | PHASE3 | COMPLETED | Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age |
| NCT05323461 | PHASE3 | UNKNOWN | A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines |
| NCT05329220 | PHASE3 | COMPLETED | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 |
| NCT05354024 | PHASE2/PHASE3 | COMPLETED | Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine |
| NCT05543356 | PHASE3 | WITHDRAWN | COVID-19 Fourth Dose Study in Australia |
| NCT05668065 | PHASE3 | COMPLETED | Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines |
| NCT04894435 | PHASE2 | ACTIVE_NOT_RECRUITING | Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity |
| NCT07390968 | PHASE2 | NOT_YET_RECRUITING | Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients |
| NCT04380701 | PHASE1/PHASE2 | COMPLETED | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults |
| NCT04649021 | PHASE2 | COMPLETED | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population |
| NCT04800133 | PHASE2 | UNKNOWN | Covid-19 Vaccination in Adolescents and Children |
| NCT04889209 | PHASE1/PHASE2 | COMPLETED | Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines |
| NCT04895982 | PHASE2 | COMPLETED | Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years |
| NCT04907331 | PHASE2 | UNKNOWN | Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2 |
| NCT04949490 | PHASE2 | COMPLETED | A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects |
| NCT05000216 | PHASE2 | TERMINATED | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders |
| NCT05004181 | PHASE2 | COMPLETED | Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants |
| NCT05016622 | PHASE2 | TERMINATED | Booster Dose Trial |
| NCT05132855 | PHASE1/PHASE2 | UNKNOWN | The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine |
| NCT05160766 | PHASE2 | COMPLETED | Assessing Immune Response of Different COVID-19 Vaccines in Older Adults |
| NCT05238441 | PHASE2 | UNKNOWN | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine |
| NCT05238454 | PHASE2 | UNKNOWN | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine |
| NCT05239806 | PHASE2 | UNKNOWN | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine |
| NCT05239975 | PHASE2 | WITHDRAWN | A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine |
| NCT05289037 | PHASE2 | COMPLETED | COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) |
| NCT05324319 | PHASE2 | UNKNOWN | Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients |
| NCT05329051 | PHASE2 | UNKNOWN | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years |
| NCT05378191 | PHASE2 | UNKNOWN | Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose |
| NCT05602961 | PHASE1/PHASE2 | WITHDRAWN | A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster |
| NCT05977127 | PHASE2 | TERMINATED | Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly |
| NCT04569383 | PHASE1 | COMPLETED | Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 |
| NCT05394012 | PHASE1 | UNKNOWN | A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 |
| NCT05396573 | PHASE1 | UNKNOWN | A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 |
| NCT04834869 | Not specified | RECRUITING | COVID-19 Vaccines Safety Tracking (CoVaST) |
| NCT05032976 | Not specified | ACTIVE_NOT_RECRUITING | Korea Comirnaty Post-marketing Surveillance |
| NCT06923137 | Not specified | ACTIVE_NOT_RECRUITING | A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19 |
| NCT04743388 | Not specified | UNKNOWN | Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System |
| NCT04815031 | Not specified | COMPLETED | Drug Use Investigation of COMIRNATY Intramuscular Injection |
| NCT04826770 | Not specified | UNKNOWN | Adaptive Immune Response to COVID-19 Vaccination |
| NCT04848584 | Not specified | COMPLETED | Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California |
| NCT04880447 | Not specified | COMPLETED | Special Investigation of COMIRNATY in the Population With Underlying Diseases |
| NCT04898946 | Not specified | COMPLETED | Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong |
| NCT04993560 | Not specified | COMPLETED | Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain |
| NCT05020145 | Not specified | COMPLETED | COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States |
| NCT05308680 | Not specified | COMPLETED | Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers |
| NCT05429047 | Not specified | UNKNOWN | Priming of the NEonatal Immune System by Transfer of Maternal Immunity |
| NCT05621239 | Not specified | COMPLETED | A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People |
| NCT05697705 | Not specified | COMPLETED | Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study |
| NCT05765578 | Not specified | COMPLETED | An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5) |
| NCT05774418 | Not specified | COMPLETED | Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital. |
| NCT05781191 | Not specified | COMPLETED | Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine |
| NCT05858450 | Not specified | COMPLETED | This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times. |
| NCT06743334 | Not specified | COMPLETED | Secondary Databased Post-marketing Surveillance Study of BNT162b2 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: severe acute respiratory syndrome
- In clinical trials for: allergic disease, neoplasm